DERM News and Press, Journey Medical Corporation From 07/11/23

2023-07-11 08:20:47 ET Viridian Therapeutics VRDN -19% following thyroid eye disease asset data . ADC Therapeutics ( ADCT ) -16% announces voluntary pause of enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in unfit or frail previously untre...

2023-07-09 03:09:09 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead

2023-07-08 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2023-07-07 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-07-03 11:49:42 ET Shares of Journey Medical ( NASDAQ: DERM ) rallied 20% in midday trading Monday following news that it expects to receive topline results the week of July 10 from two Phase 3 clinical trials for its dermatology drug DFD-29 in the treatment of rosacea. The ...

2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...

SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment o...

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance Topl...

2023-05-23 10:08:04 ET Gainers: CohBar ( CWBR ) +157% . Ocean Biomedical ( OCEA ) +79% . Shuttle Pharmaceuticals ( SHPH ) +46% . Icosavax ( ICVX ) +31% . Recursion Pharmaceuticals ( RXRX ) +20% . Losers: NantHealth ( ...

2023-05-22 18:50:25 ET Journey Medical Corp (DERM) Q1 2023 Earnings Conference Call May 22, 2023 04:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Founder, President and CEO Joseph Benesch - Interim CFO Conference Call Participants ...